Search Articles — Sudonull

Search Results

In this project

Tesla Patent: Two Batteries for Cybertruck

https://sudonull.com/tesla-patent-two-batteries-for-cybertruck

Details of the patent for the dual-battery range extender system for Cybertruck with DC/DC and trailer option. Technical breakdown for developers. Study the 800/400 V diagram.

Apple patent for Vision Pro battery with ionic liquids: 5000 cycles

https://sudonull.com/apple-patent-for-vision-pro-battery-with-ionic-liquids-5000-cycles

Apple patented a battery for Vision Pro with ionic liquids: charging up to 80% in 9 minutes, lifespan of 5000 cycles. What does this mean for the market and future devices? Read the analysis.

From other projects

Smart drugs for cancer and HIV: development by Siberian scientists

https://ymaho.com/smart-drugs-for-cancer-and-hiv-development-by-siberian-scientists

Institute of the Siberian Branch of the Russian Academy of Sciences creates therapeutic oligonucleotides — molecules that switch off cancer and HIV genes. The development of phosphorylguanidines promises treatment without side effects. Learn how Russian genetic engineering bypasses Western patents.

AI on ECG Diagnoses Heart Amyloidosis: US Patent

https://ymaho.com/ai-on-ecg-diagnoses-heart-amyloidosis-us-patent

AccurKardia Patent for AI Diagnosis of Cardiac Amyloidosis by ECG: Early Screening, Accuracy and Patient Benefits. Learn How the Technology is Changing Cardiology.

Moderna vaccine shrank tumors in 83% of melanoma patients

https://ymaho.com/moderna-vaccine-shrank-tumors-in-83-of-melanoma-patients

mRNA drug mRNA-4359 with Keytruda showed 83% response and 17% complete remissions. Even PD-L1-negative tumors shrank. Learn how a ready-made vaccine teaches the immune system to attack cancer without personalization.

6.9% of people receive effective psychiatric treatment

https://ymaho.com/6-9-of-people-receive-effective-psychiatric-treatment

Only 6.9% of patients with mental disorders receive effective treatment. Learn about global system failures and hidden causes of the crisis. Detailed analysis.

Vyvgart approved for all serotypes of myasthenia gravis

https://ymaho.com/vyvgart-approved-for-all-serotypes-of-myasthenia-gravis

FDA expanded Vyvgart indications to all patients with generalized myasthenia gravis. Learn how this will change the treatment market. Read analysis.

FDA approved the first gene therapy for hereditary deafness

https://ymaho.com/fda-approved-the-first-gene-therapy-for-hereditary-deafness

Regeneron's Otarmeni restores hearing to normal in 42% of patients. The therapy treats OTOF gene mutations with a single injection. Learn how AAV vector technology has for the first time restored the ability to hear a whisper.

Survodutide in obesity: 13% efficacy in phase 3

https://ymaho.com/survodutide-in-obesity-13-efficacy-in-phase-3

The new dual agonist Survodutide showed 13% weight reduction in patients with obesity without diabetes. Learn about the mechanism of action, side effects, and prospects of the drug.

Trending Now